Cargando…

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors

BACKGROUND: Pharmacokinetic (PK) studies suggest that talazoparib is primarily eliminated unchanged via renal excretion. The current study investigated how varying degrees of renal impairment may affect the PK of talazoparib, and evaluated the safety and tolerability of talazoparib, in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durairaj, Chandrasekar, Chakrabarti, Jayeta, Ferrario, Cristiano, Hirte, Holger W., Babu, Sunil, Piha-Paul, Sarina A., Plotka, Anna, Hoffman, Justin, Shi, Haihong, Wang, Diane D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249284/ https://www.ncbi.nlm.nih.gov/pubmed/33686631 http://dx.doi.org/10.1007/s40262-020-00983-y

Ejemplares similares

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
por: Guo, Cen, et al.
Publicado: (2022)

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
por: Hoffman, Justin, et al.
Publicado: (2019)

Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours
por: Elmeliegy, Mohamed, et al.
Publicado: (2020)

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors
por: Luo, Yang, et al.
Publicado: (2023)

Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study
por: Naito, Yoichi, et al.
Publicado: (2021)

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method
por: Talebi, Zahra, et al.
Publicado: (2023)

Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics
por: Purohit, Vivek, et al.
Publicado: (2023)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
por: Leal, Ticiana A., et al.
Publicado: (2022)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

A Phase I trial of talazoparib in patients with advanced hematologic malignancies
por: Gopal, Ajay K, et al.
Publicado: (2021)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer
por: Wang, Tao, et al.
Publicado: (2022)

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma
por: Del Pozo, Vanessa, et al.
Publicado: (2021)

Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
por: Schwarz, Florian, et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)

Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2021)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model
por: Baldwin, Paige, et al.
Publicado: (2019)

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
por: Lakomy, David S., et al.
Publicado: (2019)

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies
por: Kohl, Vanessa, et al.
Publicado: (2019)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Zou, Denise, et al.
Publicado: (2021)

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
por: Wong, Fu Hou, et al.
Publicado: (2022)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
por: Polyanskaya, Elizaveta, et al.
Publicado: (2023)

Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
por: Fu, Wenyan, et al.
Publicado: (2023)

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
por: Grechko, Nikolay, et al.
Publicado: (2021)

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors
por: Fu, S., et al.
Publicado: (2017)

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors
por: Fu, S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oehllgp9nm8egf5iqsvfa80ftc